SynAct Pharma has signed a 50/50 co-development and commercialisation agreement with Hipolabor in Brazil. The deal covers dengue in one of the world’s largest markets and is the first commercial partnership for resomelagon. SynAct retains full control of the asset and flexibility for further deals in other indications and regions. BioStock contacted SynAct’s CBO Mads Bjerregaard for a comment.
Read the full interview at biostock.se:
SynAct on signing resomelagon’s first commercial partner
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/